NCT00654407View on ClinicalTrials.gov

Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

4,875

Participants

Timeline

Start Date

November 30, 2001

Study Completion Date

September 30, 2004

Conditions
Hypercholesterolemia
Interventions
DRUG

Rosuvastatin

DRUG

Atorvastatin

DRUG

Simvastatin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY